Kerstin Luhn
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses.
Journal: Science translational medicine
Published: April 02, 2025
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Journal: Human vaccines & immunotherapeutics
Published: March 25, 2024
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.
Journal: Vaccines
Published: March 20, 2024
Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.
Journal: The Journal of infectious diseases
Published: March 15, 2024
Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines.
Journal: Journal of thrombosis and haemostasis : JTH
Published: March 15, 2024
Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.
Journal: Frontiers in immunology
Published: February 08, 2024
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 01, 2023
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Journal: Vaccine
Published: May 23, 2023
Last Updated: 09/26/2026